Singapore Paincare (SGX:FRQ) disclosed a qualified opinion from auditors BDO LLP for its financial statements for the year ended June 30, 2024, according to a Thursday filing on the Singapore Exchange.
The group's goodwill, valued at $13.5 million, was assessed for impairment using a value-in-use method, with no impairment loss recognized. The assessment of investments in subsidiaries, totaling around $5 million, also showed no impairment loss.
Additionally, the fair value of financial assets held by the group's joint venture, Singapore Paincare Capital, was recorded at about $8.8 million, contributing to a fair value gain of $578,000.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。